Antiphospholipid syndrome and acute myocardial infarction: Treatment with thrombectomy and abciximab
We report an adult male patient with APS who presented with an acute myocardial infarction. Given the high risk of thrombosis in these patients, he was treated percutaneously with thrombectomy and abciximab. We review the few cases of coronary angioplasty in patients with APS reported to date. To our knowledge, this is the first case in which acute myocardial infarction due to thrombotic coronary occlusion was treated with thrombectomy and abciximab without stenting the artery. (Source: Revista Portuguesa de Cardiologia)
Source: Revista Portuguesa de Cardiologia - November 6, 2014 Category: Cardiology Source Type: research
Recanalization of acute carotid stent occlusion using Penumbra 4Max aspiration catheter: technical report and review of rescue strategies for acute carotid stent occlusion
Carotid artery stenting (CAS) has become a widely used treatment for carotid artery stenosis, especially in high-risk patients. Acute in-stent and distal protection device occlusion are potentially catastrophic complications of this procedure. Previously described rescue strategies have included administration of antiplatelet agents (eg, abciximab) with/without thrombolytics and removal of the filter. Here we describe the successful resolution of in-stent occlusion by mechanical thrombolysis using the Penumbra 4Max aspiration catheter. Distal flow was subsequently restored with minimal residual stenosis. The patient did no...
Source: Journal of NeuroInterventional Surgery - September 5, 2014 Category: Neurosurgery Authors: Munich, S., Moftakhar, R., Lopes, D. Tags: Electronic pages Source Type: research
Efficacy and Time-To-Hemostasis of Antegrade Femoral Access Closure Using the ExoSeal Vascular Closure Device: A Retrospective Single-Center Study.
CONCLUSION: ExoSeal vascular closure of antegrade femoral punctures is safe and effective with a low complication rate. Two minutes of MC are sufficient to achieve hemostasis in the majority of cases. However, in patients on antiplatelet therapy, especially after abciximab, the authors advocate prolonging MC to 5 minutes.
PMID: 25201516 [PubMed - as supplied by publisher] (Source: PubMed: Eur J Vasc Endovasc ...)
Source: PubMed: Eur J Vasc Endovasc ... - September 5, 2014 Category: Surgery Authors: Boschewitz JM, Pieper CC, Andersson M, Nadal J, Schild HH, Meyer C Tags: Eur J Vasc Endovasc Surg Source Type: research
αIIbβ3-Integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells.
This study presents effects of two αIIbβ3-inhibitors: Abciximab and Eptifibatide on apoptosis, expression of proline oxidase (POX), signaling molecules ERK 1/2, transcription factor NF-κB and HIF-1α, vascular endothelial growth factor (VEGF) as well as DNA biosynthesis, collagen biosynthesis and prolidase activity in MCF-7 breast cancer cells. Both ligands induced apoptosis, however we found significant differences in molecular mechanism of action between tested αIIbβ3-inhibitors. These differences include expression of POX, HIF-1α, NF-κB,VEGF and collagen biosynthesis. Eptifibatide presented stronger proapoptotic ...
Source: Current Drug Targets - August 4, 2014 Category: Drugs & Pharmacology Authors: Kononczuk J, Surazynski A, Czyzewska U, Prokop I, Tomczyk M, Palka J, Miltyk W Tags: Curr Drug Targets Source Type: research
Effects of Baseline Coronary Occlusion and Diabetes Mellitus in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Several studies have highlighted the prognostic role of preprocedural Thrombolysis In Myocardial Infarction (TIMI) flow in the infarct-related artery (IRA) in patients with ST-segment elevation myocardial infarction (STEMI). However, the impact of preprocedural IRA occlusion in patients with diabetes with STEMI has been insufficiently studied. The aim of this study was to evaluate the effects of baseline IRA occlusion and diabetic status in patients with STEMI who underwent primary percutaneous coronary intervention by using data from a pooled analysis of randomized trials comparing intracoronary with intravenous abciximab...
Source: The American Journal of Cardiology - July 29, 2014 Category: Cardiology Authors: Raffaele Piccolo, Gennaro Galasso, Allan Zeeberg Iversen, Ingo Eitel, Alberto Dominguez-Rodriguez, Youlan L. Gu, Bart J.G.L. de Smet, Karim D. Mahmoud, Pedro Abreu-Gonzalez, Bruno Trimarco, Holger Thiele, Federico Piscione Tags: Coronary Artery Disease Source Type: research
E-056 Pipeline Endovascular Device for the Treatment of Intracranial Aneurysm at the Level of the Circle of Willis and Beyond: Multicenter Experience
Conclusion
The PED provides a safe and effective solution for aneurysms at and beyond the circle of Willis. Preliminary results are promising but larger series with longer-term follow-up examinations are required to show the long-term safety and durability of this treatment alternative.
Disclosures
M. Martínez-Galdámez: 2; C; Covidien. I. Linfante: 2; C; Covidien, Stryker, Codman. E. Lin: None. G. Dabus: 2; C; Covidien, Microvention, Reverse Medical. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 26, 2014 Category: Neurosurgery Authors: Martinez-Galdamez, M., Linfante, I., Lin, E., Dabus, G. Tags: Electronic poster abstracts Source Type: research
Impact of Long-Term Statin Pretreatment on Myocardial Damage in ST Elevation Myocardial Infarction (from the AIDA STEMI CMR Substudy)
In conclusion, in this CMR study, statin pretreatment in patients with STEMI was not associated with lesser myocardial damage. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - June 9, 2014 Category: Cardiology Authors: Georg Fuernau, Ingo Eitel, Jochen Wöhrle, Sebastian Kerber, Bernward Lauer, Matthias Pauschinger, Johannes Schwab, Ralf Birkemeyer, Stefan Pfeiffer, Meinhard Mende, Oana Brosteanu, Petra Neuhaus, Steffen Desch, Suzanne de Waha, Matthias Gutberlet, Gerhar Tags: Coronary Artery Disease Source Type: research
Effect of polymer-free TiO2 stent coated with abciximab or alpha lipoic acid in porcine coronary restenosis model.
CONCLUSION: TCA and TCALA are more effective to reduce neointimal hyperplasia compared to TC. Moreover, fibrin and inflammation scores are significantly lower in TCA and TCALA than BES in porcine coronary restenosis model.
PMID: 24852847 [PubMed - as supplied by publisher] (Source: Journal of Cardiology)
Source: Journal of Cardiology - May 19, 2014 Category: Cardiology Authors: Lim KS, Jeong MH, Bae IH, Park JK, Park DS, Kim JM, Kim JH, Kim HS, Kim YS, Jeong HY, Song SJ, Yang EJ, Cho DL, Sim DS, Park KH, Hong YJ, Ahn Y Tags: J Cardiol Source Type: research
Efficacy of Combination Treatment with Intracoronary Abciximab and Aspiration Thrombectomy on Myocardial Perfusion in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Stenting.
CONCLUSION: Combination treatment using IC abciximab and AT may synergistically improve myocardial perfusion in patients with STEMI undergoing primary PCI (Trial Registration: clinicaltrials. gov Identifier: NCT01404507).
PMID: 24719126 [PubMed - in process] (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - April 13, 2014 Category: Universities & Medical Training Authors: Ahn SG, Lee SH, Lee JH, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Yoon J, Choe KH, Tahk SJ Tags: Yonsei Med J Source Type: research
Impact of multivessel disease on infarct size among STEMI patients undergoing primary angioplasty
Abstract: Background: Although primary angioplasty achieves Thrombolysis In Myocardial Infarction (TIMI) 3 flow in most patients with ST-elevation myocardial infarction, epicardial recanalization does not guarantee optimal perfusion in a large proportion of patients. Multivessel disease has been demonstrated to be associated with impaired survival, however its impact on infarct size has not been largely investigated, that therefore is the aim of the current study.Methods: Our population is represented by 827 STEMI patients undergoing primary PCI. Infarct size was evaluated at 30 days by technetium-99m-sestamibi.Results: Mu...
Source: Atherosclerosis - April 10, 2014 Category: Cardiology Authors: Giuseppe De Luca, Guido Parodi, Roberto Sciagrà, Benedetta Bellandi, Vincenzo Comito, Ruben Vergara, Angela Migliorini, Renato Valenti, David Antoniucci Tags: Clinical & Population Research – Intervention Source Type: research
Downstream Clot Fragment Migration During Endovascular Clot Extraction Adversely Affects Clinical Outcome (P4.212)
Conclusion: Our results strongly suggest an adverse effect of downstream clot fragments. Awareness of this should become part of the approval and post-marketing evaluation of devices.Disclosure: Dr. Frey has received personal compensation for activities with Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Co., EKT Pharma, Genentech Inc., and Sanofi-Aventis Pharmaceuticals Inc. Dr. Darbonne has nothing to disclose. Dr. Clark has nothing to disclose. Dr. Tucker has nothing to disclose. Dr. Chapple has nothing to disclose. (Source: Neurology)
Source: Neurology - April 9, 2014 Category: Neurology Authors: Frey, J., Darbonne, C., Clark, J., Tucker, A., Chapple, C. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Stroke Endovascular Source Type: research
Reply Intracoronary Versus Intravenous Abciximab Bolus Administration
We thank Dr. De Rosa and colleagues for the interest in our work (1,22). We agree that the AIDA STEMI (Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction) trial might have been underpowered to detect small differences in clinical event rates between the treatment arms (if there are any). The absolute difference in the incidence of the primary endpoint between groups was only 0.6%. Thus, if one were to plan a new trial with a similar design considering this numerical difference as the true population value, the required total sample size would exceed 70,000 patients to reach statistical significance. It remain...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - March 31, 2014 Category: Cardiology Source Type: research
Intracoronary Versus Intravenous Abciximab Bolus Administration
We read with interest the recently published paper by Desch et al. (1) reporting on long-term clinical follow-up of the randomized AIDA STEMI (Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction) trial. (Source: Journal of the American College of Cardiology: Cardiovascular Interventions)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - March 31, 2014 Category: Cardiology Source Type: research
Delayed, severe thrombocytemia after abciximab infusion for primary angioplasty in acute coronary syndromes: Moving between systemic bleeding and stent thrombosis
Platelets, Ahead of Print. (Source: Platelets)
Source: Platelets - March 28, 2014 Category: Hematology Tags: article Source Type: research
Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era.
Abstract
In patients with an acute ST-segment elevation myocardial infarction, timely myocardial reperfusion using primary percutaneous coronary intervention is the most effective therapy for limiting myocardial infarct size, preserving left-ventricular systolic function and reducing the onset of heart failure. Within minutes after the restoration of blood flow, however, reperfusion itself results in additional damage, also known as myocardial ischemia-reperfusion injury. An improved understanding of the pathophysiological mechanisms underlying reperfusion injury has resulted in the identification of sever...
Source: World Journal of Cardiology - March 26, 2014 Category: Cardiology Authors: Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ Tags: World J Cardiol Source Type: research
